Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 2/20 | 0.37 |
| ▸ | ADRA2B known ✓ | P18089 | 2/20 | 0.37 |
| ▸ | ADRA2C known ✓ | P18825 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 4/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.35 |
| ▸ | MPI | P34949 | 1/20 | 0.35 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.35 |
| ▸ | WNT3A | P56704 | 1/20 | 0.35 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.34 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.34 |
| ▸ | C1S | P09871 | 1/20 | 0.34 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30931204 | 0.98 | MAPT (0.38) | MAPTHTTADRA2AADRA2BADRA2C | |
| SCHEMBL13886916 | 0.98 | MAPT (0.38) | MAPTHTTADRA2AADRA2BADRA2C | |
| Hydrochloric Acid SCHEMBL18694922 | 0.80 | MAPT (0.47) | MAPTHTTADRA2AADRA2BADRA2C | |
| SCHEMBL1315947 | 0.79 | MAPT (0.39) | MAPTHTTADRA2AADRA2BADRA2C | |
| Hydrochloric Acid SCHEMBL7958246 | 0.78 | GRM4 (0.40) | MAPTLMNABLMKDM4EL3MBTL1 | |
| SCHEMBL319270 | 0.78 | MAPT (0.49) | MAPTHTTLMNABLMKDM4E | |
| SCHEMBL2459394 | 0.77 | KDM4E (0.47) | MAPTLMNABLMKDM4EL3MBTL1 | |
| Hydrochloric Acid SCHEMBL17893831 | 0.76 | NOS3 (0.52) | MAPTHTTLMNABLMKDM4E | |
| Hydrochloric Acid SCHEMBL20599691 | 0.76 | KDM4E (0.36) | BLMKDM4EPRSS1PRSS2C1S | |
| Hydrochloric Acid SCHEMBL5729361 | 0.76 | LMNA (0.38) | MAPTHTTLMNABLMKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3892617-B1 | FLUORINATED PYRIMIDINE COMPOUND AND PRODUCTION METHOD THEREFOR | UNIMATEC CO LTD (JP) | 2025-04-30 | — | — | EP | disclosed |
| US-12043615-B2 | Fluorine-containing pyrimidine compound and method for manufacturing the same | UNIMATEC CO., LTD. (JP) | 2024-07-23 | — | — | US | disclosed |
| US-20210403455-A1 | FLUORINE-CONTAINING PYRIMIDINE COMPOUND AND METHOD FOR MANUFACTURING THE SAME | UNIMATEC CO., LTD. (JP) | 2021-12-30 | — | — | US | disclosed |
| EP-3892617-A1 | FLUORINATED PYRIMIDINE COMPOUND AND PRODUCTION METHOD THEREFOR | Unimatec Co., Ltd. (JP) | 2021-10-13 | — | — | EP | disclosed |
| EP-2888241-B1 | 2,4,5,6-Substituted 3,6-dihydropyrimidine derivatives as hepatitis B virus (HBV) polymerase inhibitors for the treatment of e.g. chronic hepatitis | SUNSHINE LAKE PHARMA CO LTD (CN) | 2017-07-12 | — | — | EP | disclosed |
| US-20160264536-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-09-15 | — | — | US | disclosed |
| EP-3061754-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2016-08-31 | — | — | EP | disclosed |
| US-20160237059-A1 | HETEROCYCLIC SUBSTITUTED TRIFLUOROMETHYL PYRIMIDINONES AND THEIR USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-08-18 | — | — | US | disclosed |
| US-9340538-B2 | Dihydropyrimidine compounds and their application in pharmaceuticals | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2016-05-17 | — | — | US | disclosed |
| EP-2888241-A1 | DIHYDROPYRIMIDINE COMPOUNDS AND THEIR APPLICATION IN PHARMACEUTICALS | Sunshine Lake Pharma Co., Ltd. (CN) | 2015-07-01 | — | — | EP | disclosed |
| US-20040167135-A1 | Dihydropyrimidines | BAYER AKTIENGESELLSCHAFT (DE) | 2004-08-26 | — | — | US | disclosed |
| EP-1265889-B1 | MEDICAMENTS AGAINST VIRAL DISEASES | BAYER HEALTHCARE AG (DE) | 2004-06-16 | — | — | EP | disclosed |
| US-6696451-B1 | NITROGEN COMPOUND SUCH AS ETHYL-4-(2-BROMOPHENYL)-2-(3-FLUORO PYRIDIN-2-YL)-6-METHYL-1,4-DIHYDROPYRIMIDIN-5-CARBOXYLATE, USED FOR THE PROPHYLAXIS OF VIRAL DISEASES SUCH AS HEPATITIS | BAYER AKTIENGESELLSCHAFT (DE) | 2004-02-24 | — | — | US | disclosed |
| US-20030232842-A1 | Medicaments against viral diseases | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2003-12-18 | — | — | US | disclosed |
| EP-1265889-A1 | MEDICAMENTS AGAINST VIRAL DISEASES | Bayer Aktiengesellschaft (DE) | 2002-12-18 | — | — | EP | disclosed |
| EP-1080086-B1 | DIHYDROPYRIMIDINES | BAYER AG (DE) | 2002-09-04 | — | — | EP | disclosed |
| WO-2001068640-A1 | MEDICAMENTS AGAINST VIRAL DISEASES | BAYER AKTIENGESELLSCHAFT (DE) | 2001-09-20 | — | — | WO | disclosed |
| WO-2001068642-A1 | DIHYDROPYRIMIDINES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | BAYER AKTIENGESELLSCHAFT (DE) | 2001-09-20 | — | — | WO | disclosed |
| WO-2001068647-A1 | MEDICAMENTS AGAINST VIRAL DISEASES | BAYER AKTIENGESELLSCHAFT (DE) | 2001-09-20 | — | — | WO | disclosed |
| WO-2000058302-A1 | DIHYDROPYRIMIDINES AND THEIR USE IN THE TREATMENT OF HEPATITIS B | BAYER AKTIENGESELLSCHAFT (DE) | 2000-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167135-A1 | Dihydropyrimidines | DPYD, DHFR, DHPS | ADRA2A 3390/4885ADRA2B 2312/4885ADRA2C 3078/4885 |
| US-12043615-B2 | Fluorine-containing pyrimidine compound and method for manufacturing the same | CNOT1, NUDT1, XRN2 | ADRA2A 1258/4885ADRA2B 2008/4885ADRA2C 2580/4885 |
| US-20030232842-A1 | Medicaments against viral diseases | HAVCR2, ENTPD5, TYMP | ADRA2A 4012/4885ADRA2B 3904/4885ADRA2C 4234/4885 |
| US-20210403455-A1 | FLUORINE-CONTAINING PYRIMIDINE COMPOUND AND METHOD FOR MANUFACTURING THE SAME | CNOT1, NUDT1, XRN2 | ADRA2A 1258/4885ADRA2B 2008/4885ADRA2C 2580/4885 |
| US-20160264536-A1 | HETEROCYCLIC COMPOUND | PDE2A, PDE5A, PDE3A | ADRA2A 98/4885ADRA2B 268/4885ADRA2C 114/4885 |
| US-20160237059-A1 | HETEROCYCLIC SUBSTITUTED TRIFLUOROMETHYL PYRIMIDINONES AND THEIR USE | REN, GLS, FIBP | ADRA2A 683/4885ADRA2B 639/4885ADRA2C 275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.